John Evans, Beam Therapeutics CEO
Beam doses first patient with base-edited cell therapy
Beam Therapeutics announced Tuesday that it dosed its first patient with its base-edited CAR-T treatment last month.
BEAM-201 is an off …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
